New First-Line Treatment: Metastatic Triple-Negative Breast Cancer with Dr. Sara Tolaney (Dana-Farber Cancer Inst.)

<p>This episode is sponsored by Gilead Sciences. Gilead had no involvement or input in the podcast content. Gilead is working to transform how cancer is treated. We are innovating with next-generation therapies, combinations, and technologies to deliver improved outcomes for people with cancer. From antibody drug conjugates and small molecules to cell therapy-based approaches, our portfolio and pipeline assets are creating new possibilities for people with cancer.</p><p><br /></p><p>Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, returns to Patient From Hell to explain the ASCENT-04/KEYNOTE-D19 study, the phase 3 trial she led as principal investigator, and what it changes for people living with metastatic triple-negative breast cancer.For years, the most effective drugs for metastatic TNBC were only available after first-line chemotherapy had already failed. The problem, as Dr. Tolaney puts it plainly, is that many patients never reach a second line of treatment at all. ASCENT-04 asked whether moving an antibody-drug conjugate to the front, paired with immunotherapy, would change that. Median progression-free survival improved from 7.8 months to 11.2 months, and treatment responses lasted significantly longer.</p><p><br /></p><p>UPDATE: Since this recorded conversation, the FDA has acted on the data discussed in this episode. On May 22, 2026, Datopotamab Deruxtecan was approved for first-line metastatic TNBC in patients who are not candidates for immunotherapy. On June 24, 2026, Sacituzumab Govitecan was approved for first-line use both as a single agent and in combination with pembrolizumab for PD-L1-positive disease (CPS ≥10). Consult with your care team for the most recent indications and availability of these treatment options.</p><p><br /></p><p>00:00 The trial that moves the best drugs first </p><p>00:31 Welcome back, Dr. Sara Tolaney </p><p>00:40 What ASCENT-04 set out to solve </p><p>02:00 Why many patients never reach second-line treatment </p><p>02:50 What PD-L1 status means for your treatment </p><p>04:12 The result: 7.8 to 11.2 months </p><p>05:29 What is an antibody-drug conjugate (ADC)? </p><p>06:33 Why TROP-2 is the target in triple-negative breast cancer </p><p>07:24 How immunotherapy works: taking the brakes off the T cell </p><p>09:01 Who was eligible for the trial </p><p>10:05 What "controlling" cancer actually means </p><p>11:44 Progression-free survival vs. duration of response </p><p>13:37